NCT03258151

Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 2,200 (estimated)
• Sponsor: Cui Yimin · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Taxanes are one of the most active agents in the treatment of many kinds of solid tumors, mainly including paclitaxel and docetaxel. However, variability in toxicity and response remains a major problem for patients receiving taxanes. It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Toxicities of docetaxel, such as myelosuppression, neurotoxicity or mucositis, were evaluated for possible relationship with pharmacogenetic polymorphisms in several candidate gene and genome-wide association studies. Due to the levels of evidence of those studies are low and lack of sufficient research data of Chinese, it has the important significance in studying individual differences of docetaxel in toxicities, through the pharmacogenomics research. The aim of this study is to evaluating the association genetic polymorphisms with docetaxel-based chemotherapy toxicities in chinese solid tumor patients. By detecting the gene polymorphism, investigators intend to study the pharmacokinetic/pharmacogenomics (PK-PG) correlation of docetaxel and provide scientific basis for precise medication guide for people to use docetaxel.

Conditions

• Solid Tumors
• Docetaxel
• Drug-Related Side Effects and Adverse Reactions
• Pharmacogenetics
• Pharmacokinetics

Interventions

Type	Name	Description
GENETIC	detection of genotype	detection of genotype by next generation sequencing

Timeline

• Start date: 2017-09-25
• Primary completion: 2019-09-01
• Completion: 2019-12-01
• First posted: 2017-08-23
• Last updated: 2019-08-28

Locations

6 sites across 1 country: China